The lack of diversity in clinical trials is a serious problem that’s persisted for decades. Black Americans—who make up 20 percent of US multiple myeloma patients and are twice as likely to be diagnosed—have only accounted for 4.5 percent of participants in multiple myeloma trials since 2003. Asian Americans—who make up nearly 6 percent of the U.S. population—have accounted for less than 2 percent of US-based trials.
The reality is that diverse patient populations have different responses to certain pharmaceuticals, and ignoring this poses a significant community and global health risk.
A critical reason behind this… Read more »
UNDERWRITERS AND PARTNERS